Serotype B Meningococcal Vaccine

1. See Also
   1. Meningococcal Vaccine (Menactra, Menveo, MCV4)
   2. Menomune (MPSV4)
   3. Neisseria Meningitidis
   4. Bacterial Meningitis
2. Indications (age 10 years old or older)
   1. Serotype B Meningococcal Meningitis exposure
   2. Asplenia
   3. Sickle Cell Disease
   4. Specific immune deficiency
3. Mechanism
   1. Covers only Serotype B Meningococcus
      1. Accounts for one third of meningococcal cases
      2. Serotype B outbreaks are most common in infants and college students
   2. Contrast with Menactra, Menveo and Menomune which cover serotypes A, C, W and Y
      1. Indicated for all U.S. children as part of the Primary Series
4. Preparations (FDA approved in 2014)
   1. Must use same preparation for both doses (not interchangeable)
   2. MenB-FHbp (Trumenba)
      1. Two dose regimen at least 6 months apart (0 and 6 months)
         1. Two dose regimen may be used for healthy patients ages 16-23 years AND
         2. Not at increased meningococcal disease
      2. Three dose series (0, 2 and 6 months)
         1. Indicated for Asplenia, complement deficiency, or complement inhibitor
   3. MenB-4C (Bexsero)
      1. Two dose series at least 1 month apart (0 and 1-6 months)
5. Resources
   1. CDC Immunization Schedules (last accessed 10/28/2020)
      1. https://www.cdc.gov/vaccines/schedules/
6. References
   1. Jacobson (2017) Vaccine Update,Mayo Clinic Reviews, Rochester, MN
   2. (2015) Presc Lett 22(10): 59
   3. Ackerman (2015) Am Fam Physician 92(6): 460-8 [PubMed]
   4. Cohn (2013) MMWR Recomm Rep 62(RR-2):1-28 [PubMed]